Free minds from bleeding damage.
Developing a potential first-in-class Protein S-targeting siRNA platform for inherited bleeding disorders.
Proposition
BLEEDnFIRE is a Switzerland-based biotechnology company developing RNA-based therapies for bleeding disorders. Our lead program, BnF-001, is a GalNAc-conjugated siRNA designed to selectively reduce hepatic Protein S and restore thrombin generation through controlled rebalancing of coagulation.
This approach is being developed across von Willebrand disease, Glanzmann thrombasthenia, hemophilia A, with the potential to address both bleeding burden and treatment burden through a single mechanism.
A new approach to bleeding disorders
Rebalancing coagulation through siRNA
Potential for infrequent
subcutaneous dosing
One mechanism across
bleeding and joint disease
BnF-001
BnF-001 is the only siRNA therapeutic targeting Protein S known to us in development for major bleeding disorders. Preclinical and translational data support its potential to restore thrombin generation across multiple disease settings, with additional effects on bleeding control, joint preservation, and bone integrity.
Team
Built on science.
Designed for translation.
BLEEDnFIRE brings together expertise in hemostasis, RNA therapeutics, drug development, CMC, strategy, commercialization and company building to advance a differentiated therapeutic platform from discovery toward the clinic.
Supported by leading Swiss innovation and academic institutions.
